Department of Surgery, Yokohama City University, Yokohama, Japan;
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Anticancer Res. 2024 May;44(5):2185-2192. doi: 10.21873/anticanres.17025.
BACKGROUND/AIM: Recently, the prognostic immune and nutritional index (PINI) was developed and reported to be a promising nutritional and inflammatory prognostic marker. The aim of the present study was to clarify the clinical impact of the PINI for esophageal cancer patients who received curative treatment.
We conducted a retrospective review of medical records and collected data on consecutive esophageal cancer patients who underwent curative resection at Yokohama City University between 2005 and 2020. The PINI was calculated by dividing the serum ALB concentration (g/dl) by the serum monocyte concentration, both of which were measured before surgery.
A total of 180 patients were included in this study. The cutoff value of the PINI was 3.0 in the present study. The 3- and 5-year overall survival rates were 45.2% and 33.5%, respectively, in the PINI-low subgroup, and 69.1% and 61.8%, respectively, in the PINI-high subgroup. A multivariate analysis demonstrated that the PINI was an independent prognostic factor for overall survival (hazard ratio=2.091, 95% confidence interval=1.287-3.399, p=0.003). Similar results were observed for recurrence-free survival. When comparing the sites of recurrence between the two groups, the incidence of hematological recurrence was significantly greater in the PINI-low subgroup compared to the PINI-high subgroup (46.8% vs. 21.1%, p<0.001).
The PINI is a promising nutritional and inflammatory marker for esophageal cancer patients. The PINI might be a useful marker for the treatment and management of esophageal cancer patients.
背景/目的:最近,预后免疫和营养指数(PINI)被开发并报道为一种有前途的营养和炎症预后标志物。本研究旨在阐明 PINI 对接受根治性治疗的食管癌患者的临床影响。
我们对连续接受根治性切除术的食管癌患者的病历进行了回顾性审查,并收集了 2005 年至 2020 年在横滨市立大学接受治疗的数据。PINI 通过术前测量的血清 ALB 浓度(g/dl)除以血清单核细胞浓度计算得出。
本研究共纳入 180 例患者。在本研究中,PINI 的截断值为 3.0。PINI 低亚组的 3 年和 5 年总生存率分别为 45.2%和 33.5%,而 PINI 高亚组分别为 69.1%和 61.8%。多因素分析表明,PINI 是总生存率的独立预后因素(危险比=2.091,95%置信区间=1.287-3.399,p=0.003)。无复发生存率也得到了类似的结果。在比较两组之间的复发部位时,PINI 低亚组的血液学复发发生率明显高于 PINI 高亚组(46.8%比 21.1%,p<0.001)。
PINI 是食管癌患者有前途的营养和炎症标志物。PINI 可能是食管癌患者治疗和管理的有用标志物。